Experiences with the shikimate-pathway enzymes as targets for rational drug design.
The background and current context of work on the shikimate-pathway enzymes as potential targets for anti-bacterial, anti-fungal and anti-parasitic drugs is reviewed. Recent work on the third enzyme of the pathway, dehydroquinase, which occurs in two structurally and mechanistically distinct forms, is used to illustrate the present state of studies into rational drug design.
Coggins
J R
JR
Division of Biochemistry & Molecular Biology, Institute of Biomedical & Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK. j.coggins@bio.gla.ac.uk
Abell
C
C
Evans
L B
LB
Frederickson
M
M
Robinson
D A
DA
Roszak
A W
AW
Lapthorn
A P
AP
D001419:Bacteria / Q000187:drug effects / Q000201:enzymology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D006836:Hydro-Lyases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D010944:Plants / Q000201:enzymology; D012765:Shikimic Acid / Q000378:metabolism*
D004791:Enzyme Inhibitors; D012765:Shikimic Acid; D006836:Hydro-Lyases; C020000:3-dehydroquinate dehydratase